EN | UA
EN | UA

Help Support

Back

Mepolizumab is valuable to treat symptoms in asthma patients with chronic rhinosinusitis and nasal polyps

Mepolizumab is valuable to treat symptoms in asthma patients with chronic rhinosinusitis and nasal polyps Mepolizumab is valuable to treat symptoms in asthma patients with chronic rhinosinusitis and nasal polyps
Mepolizumab is valuable to treat symptoms in asthma patients with chronic rhinosinusitis and nasal polyps Mepolizumab is valuable to treat symptoms in asthma patients with chronic rhinosinusitis and nasal polyps

This prospective, observational, real-life study was carried to determine the efficacy of mepolizumab (anti-interleukin-5 monoclonal antibody) on sino-nasal symptoms, polyp growth, and asthma control in asthma patients having chronic rhinosinusitis and nasal polyposis.

See All

Key take away

In individuals having severe eosinophilic asthma and concomitant chronic rhinosinusitis and nasal polyposis, mepolizumab leads to improvement in sino-nasal and asthma symptoms and minimizes polyp growth. 

Background

This prospective, observational, real-life study was carried to determine the efficacy of mepolizumab (anti-interleukin-5 monoclonal antibody) on sino-nasal symptoms, polyp growth, and asthma control in asthma patients having chronic rhinosinusitis and nasal polyposis.

Method

The 12-month study incorporated 44 asthma subjects suffering from chronic rhinosinusitis and nasal polyposis in real life. Participants were treated with subcutaneously administered mepolizumab (100 mg every four weeks) for one year. The endpoints were evaluated before (T0), after six (T6) and 12 months (T12) of therapy: Asthma control test (ACT), forced expiratory volume at 1 sec (% FEV1), Total Endoscopic Nasal Polyp Score (TENPS), and sino/nasal outcome test (SNOT-22).

Also, blood eosinophil count, prednisone consumption, and fractional exhaled nitric oxide (FENO) were estimated. In a subgroup of participants, the nasal cytology was conducted before, after six, and 12 months of mepolizumab therapy.

Result

There was a substantial decline of SNOTT-22 and TENPS from the baseline. The nasal cytology findings indicated a considerable decrease of eosinophil percentage after mepolizumab treatment, as  shown in Table 1: 


Remarkable improvements of % FEV1 and ACT, and a decline in blood eosinophils and mean prednisone consumption were also witnessed. For FENO, there was no vital decreasing trend.

Conclusion

Mepolizumab used in a real-life setting to treat severe eosinophilic asthma improves sino-nasal and asthma outcomes, minimizes polyp growth, and exerts a steroid-sparing effect in patients with concomitant chronic rhinosinusitis and nasal polyposis.

Source:

Therapeutic advances in respiratory disease

Article:

Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study

Authors:

Aikaterini Detoraki et al

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: